Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

The Acclarent acquisition provides Integra LifeSciences the ...

The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
16K Views
Comment
Sign in to post a comment